Report from Isconova AB’s (publ) Extraordinary General Meeting held on September 6, 2013

The Extraordinary General Meeting of Isconova AB (publ), held on 6  September
2013, adopted the following resolutions in accordance with proposals from the
majority shareholder Novavax, Inc:*)

The number of members of the board shall be six, with no deputy members of the
board.

As new board members for the period extending to the next AGM Stanley C. Erck,
Sven Andréasson and James F. Young was elected.  Stanley C. Erck was elected
Chairman of the Board.

The current board members Peter Wells, Björn Sjöstrand and Russell Grieg are
proposed to remain in their respective office as board members.

The remuneration to the board of directors is SEK 75,000 to each elected member
of the board with the exception of Sven Andréasson and Stanley C. Erck to which
it is proposed that no remuneration is paid (since they are employed by Isconova
and Novavax, Inc., respectively) and that the remuneration to the chairman of
the board receives SEK 175,000, i.e. the same amount as resolved at the AGM
2013, however that the remuneration shall be split between resigning members of
the board and new members of the board pro rata in relation to the part of the
year (from the AGM 2013 until the AGM 2014) during which each relevant person
has acted as board member.

The shareholders adopted revised articles of association entailing that the
Company’s name is changed from “Isconova AB” to “Novavax AB”.

The shareholders further thanked Gunnar Fernström and Bo Håkansson for their
services and time with the company.

*) Novavax, Inc. is holding more than 90 % of the shares in Isconova AB.

For more information please contact:

Sven Andréasson, CEO Isconova
Tel: 0701-60 60 60
E-mail: sven.andreasson@isconova.com

Isconova AB (publ) discloses the information provided herein pursuant to the
Swedish Securities Market Act, the Swedish Financial Instruments Trading Act
and/or NASDAQ OMX First North Rulebook. This information was submitted for
publication on 6 September 2013 at 11.30 (CET).

This press release has been published in Swedish and English. In the event of
any discrepancy in content between the language versions, the Swedish version
shall prevail.

TO THE EDITORS

About Isconova

Isconova AB is a leading international vaccine adjuvant company headquartered in
Uppsala, Sweden. With deep knowledge of vaccine systems, Isconova is developing
vaccines independently and with partners in both the human and veterinary
markets. Isconova is a subsidiary of Novavax, Inc. (NASDAQ “NVAX”).  For more
information on Isconova: www.isconova.com